Industry
Lily\'s new obesity drug retatrutide eyes beyond GLP-1 limits tagged with fatigue
Eli Lilly\'s next-generation obesity treatment retatrutide may reduce fatigue, a side effect often associated with GLP-1 drugs, by regulating energy metabolism as well as suppressing appetite. Retatrutide is designed as a triple agonist that stimulates GLP-1, GIP and glucagon receptors. This mechanism could promote fat and glycogen breakdown while boosting insulin and limiting blood sugar spikes. Gigazine said clinical data are not yet sufficient to confirm the effect.
